EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sensitivity of Platinum‐Based Chemotherapy and Efficacy of Arsenic Trioxide‐Based Non‐Platinum Chemotherapy Following the Progression of PARPi Maintenance Therapy: A Real‐World Study

Sensitivität gegenüber platinbasierter Chemotherapie und Wirksamkeit arsen(III)-oxidbasierter Nicht-Platin-Chemotherapie nach Progression unter PARPi-Erhaltungstherapie: Real-World-Studie

Rui Gou iD, Qi Xie, Haishan Ren, Hui Zhang, Tingting Wang, Ziyu Li iD, Zhenning Li, Ruichen Wang, Yingchao Yang, Xiaoyan Shen, Yi Li, Yue Wang und 2 weitere

Cancer Medicine · 2025-09 · 14 (18)

DOI: 10.1002/cam4.71208 ↗

Auf einen Blick

Bei Patient:innen mit epithelialem Ovarialkarzinom nach Progression unter PARPi war die Ansprechrate unter arsen(III)-oxidbasierter Chemotherapie höher als unter platinbasierter Chemotherapie. Eine längere PARPi-Dauer war mit kürzerem TTSP verbunden.

Fragestellung

Welche Bedeutung hat PARPi-Resistenz für die nachfolgende Chemotherapie und welche Therapie zeigte nach Progression unter PARPi die bessere Wirksamkeit?

Methode

Retrospektive Analyse von Patient:innen mit epithelialem Ovarialkarzinom von Oktober 2015 bis November 2022; Chemotherapie nach Progression unter PARPi über mehr als 6 Monate.

Ergebnisse

41 Patient:innen. 34 erhielten platinbasierte Chemotherapie, ORR 26,5 % (9/34). 7 erhielten arsen(III)-oxidbasierte Chemotherapie, ORR 57,1 % (4/7). TTSP median 3,45 Monate; >12 Monate PARPi: kürzerer TTSP als 6–12 Monate.

Schlussfolgerung der Autor:innen

PARPi-Resistenz beeinträchtigt die nachfolgende Chemotherapie. Progression nach 6 bis 12 Monaten sollte als erworbene Resistenz gelten; nicht-platinbasierte Chemotherapie, etwa arsen(III)-oxidbasierte Sequenztherapie, könnte bevorzugt sein.

Kernaussagen

  • ORR: 26,5 % unter Platin vs. 57,1 % unter arsen(III)-oxidbasierter Therapie
  • Medianes TTSP: 3,45 Monate
  • >12 Monate PARPi mit kürzerem TTSP als 6–12 Monate

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 22.09.2025. Verfasst von Rui Gou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Arsenic Trioxide, Antineoplastic Combined Chemotherapy Protocols, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Peking University People's Hospital Research and Development Fund.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cross‐resistance is observed between platinum and Poly (ADP‐ribose) polymerase inhibitors (PARPi). We aim to propose the definition of PARPi resistance and demonstrate the best therapeutic strategy for patients with PARPi resistance.

Methods

A retrospective analysis was performed on patients diagnosed with epithelial ovarian cancer from October 2015 to November 2022. Patients were treated with PARPi for more than 6 months and received chemotherapy after progression.

Results

Totally, 41 patients were enrolled, with 21 receiving PARPi for 6 to 12 months and 20 for more than 12 months. The median duration of PARPi was 12 months, and the median time to second progression (TTSP) was 3.45 months (range, 1.0–20.2 months). The Kaplan–Meier and Cox analysis revealed a significantly shorter TTSP for patients who received PARPi for more than 12 months compared to those for 6 to 12 months. After PARPi resistance, 34 (82.9%) received platinum‐based chemotherapy, with an overall response rate (ORR) of 26.5% (9/34). Seven patients (17.1%) received arsenic trioxide (ATO)‐based chemotherapy, with an ORR of 57.1% (4/7). During subsequent chemotherapy, 12/34 patients switched to ATO‐based chemotherapy due to progression, of which five cases were evaluated as effective (41.7%).

Conclusion

PARPi resistance has a negative impact on the subsequent chemotherapy. The progression of the disease beyond 6 to 12 months should be considered as acquired resistance. Non‐platinum chemotherapy, such as ATO‐based combined sequential chemotherapy, may emerge as the preferred option for patients with PARPi resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arsenic TrioxideAntineoplastic Combined Chemotherapy ProtocolsOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsCarcinoma, Ovarian EpithelialHumansFemaleMiddle AgedRetrospective StudiesAgedAdultDrug Resistance, NeoplasmDisease ProgressionMaintenance ChemotherapyPlatinumTreatment Outcome

Stichwörter der Autor:innen

PARPiarsenic trioxidechemotherapy resistanceovarian cancer

Substanzen

Arsenic TrioxidePoly(ADP-ribose) Polymerase InhibitorsPlatinum

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China.
  • Department of Obstetrics and Gynecology, The People's Hospital of Qitaihe, Qitaihe, China.
  • Department of Obstetrics and Gynecology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Obstetrics and Gynecology, The People's Hospital of Qihe County, Dezhou, China.
  • Department of Obstetrics and Gynecology, Shijiazhuang People's Hospital, Shijiazhuang, China.

ORCID-Profile: Rui Gou, Ziyu Li

Förderung

  • National Natural Science Foundation of China
  • Peking University People's Hospital Research and Development Fund

Zitieren

APA

Gou, R., Xie, Q., Ren, H., Zhang, H., Wang, T., Li, Z., Li, Z., Wang, R., Yang, Y., Shen, X., Li, Y., Wang, Y., Wei, L., & Li, X. (2025). Sensitivity of Platinum‐Based Chemotherapy and Efficacy of Arsenic Trioxide‐Based Non‐Platinum Chemotherapy Following the Progression of PARPi Maintenance Therapy: A Real‐World Study. Cancer Medicine, 14(18). https://doi.org/10.1002/cam4.71208

Vancouver

Gou R, Xie Q, Ren H, Zhang H, Wang T, Li Z, et al. Sensitivity of Platinum‐Based Chemotherapy and Efficacy of Arsenic Trioxide‐Based Non‐Platinum Chemotherapy Following the Progression of PARPi Maintenance Therapy: A Real‐World Study. Cancer Medicine. 2025;14(18). doi:10.1002/cam4.71208

BibTeX
@article{Gou2025,
  author = {Gou, Rui and Xie, Qi and Ren, Haishan and Zhang, Hui and Wang, Tingting and Li, Ziyu and Li, Zhenning and Wang, Ruichen and Yang, Yingchao and Shen, Xiaoyan and Li, Yi and Wang, Yue and Wei, Lihui and Li, Xiaoping},
  title = {Sensitivity of Platinum‐Based Chemotherapy and Efficacy of Arsenic Trioxide‐Based Non‐Platinum Chemotherapy Following the Progression of PARPi Maintenance Therapy: A Real‐World Study},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {18},
  doi = {10.1002/cam4.71208}
}
Kostenlos starten →